Vaccines

A new study shows treating chronic Lyme disease reversed key Alzheimer's biomarkers, challenging medical guidelines and offering a new path for brain research.

RedHill Biopharma flips a capital deficit to positive equity, driven by savvy partnerships for its drugs Talicia and Bekinda and a promising R&D pipeline.

A landmark study reveals essential phospholipids significantly reduce liver fat and fatigue in MASLD patients, offering a new tool against a silent epidemic.

A novel alpha-radiation therapy, Alpha DaRT, begins European trials, offering a new path for pancreatic cancer patients with no other treatment options.

With its Nasdaq debut, Lakewood-Amedex aims to accelerate its novel antimicrobial, Nu-3, a new weapon against antibiotic-resistant diabetic foot ulcers.

ENA Respiratory appoints GSK veteran Melissa Faris to its board, a strategic move signaling an accelerated push for its innovative virus-agnostic nasal spray.

With a fresh CAD $1M in funding, Grey Matters is set to enter the booming U.S. neuroimaging market, targeting early Alzheimer's detection.

For the 5th straight year, WA's life sciences outpace job growth. See how AI leadership and strategic investment fuel its $43.4B economic impact.

The arrival of South Africa's first generic hormonal IUD aims to tackle high costs and low uptake of long-acting contraception in a nation of high unplanned pregnancies.

A $500K grant accelerates a novel therapy that dismantles tumor defenses, offering new hope for patients with hard-to-treat gastroesophageal cancers.

A new state-of-the-art facility in Chicago aims to secure life-saving medicines, as GEODIS enters a heated race for pharmaceutical logistics dominance.

A new drug for a life-threatening genetic heart condition begins late-stage trials, earning FDA Fast Track to potentially speed its path to patients.

New data shows Synthekine's STK-012 overcomes resistance to standard therapy, offering hope for patients with immune-cold non-small cell lung cancer.

Dizal to unveil late-breaking ZEGFROVY data for NSCLC, plus new findings for drugs tackling resistance and boosting immunotherapy at ASCO 2026.

Obsidian Therapeutics will unveil pivotal Phase 2 data on OBX-115, an engineered cell therapy that may offer a safer, more potent weapon against melanoma.

Harrington Discovery Institute opens its 2027 award call, offering millions in funding and expert support to turn academic research into life-saving medicines.

A novel drug candidate from Addex Therapeutics shows robust cough suppression in key preclinical studies, offering hope for a treatment without current side effects.

Freshly spun-off from AnaptysBio, First Tracks Biotherapeutics hits the market with a strong cash position and a pipeline aimed at celiac disease and RA.

PeptiDream and Asahi Kasei's novel drug candidate, AK1940, begins Phase 1 trials, aiming for a safer, more targeted approach to treating autoimmune diseases.

With Cigna's backing, Accord's IMULDOSA is set to challenge a blockbuster drug, promising significant savings for patients and the healthcare system.